Eli Lilly and Co banner

Eli Lilly and Co
SIX:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
SIX:LLY
Watchlist
Price: 730 CHF 2.82% Market Closed
Market Cap: CHf2.2T

Multiples-Based Value

LLY price has not been updated for more than 3 years. This may indicate that the stock has been delisted.

The Multiples-Based Value of one LLY stock under the Base Case scenario is hidden CHF. Compared to the current market price of 730 CHF, Eli Lilly and Co is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
SIX:LLY
869B CHF 13.8 43.7 29.5 31.4
US
Johnson & Johnson
NYSE:JNJ
588.6B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.4 11.5 13
UK
AstraZeneca PLC
LSE:AZN
233B GBP 5.3 30.6 16.9 23.8
US
Merck & Co Inc
NYSE:MRK
297.7B USD 4.6 16.4 10.1 12.3
CH
Novartis AG
SIX:NOVN
231.9B CHF 5.4 21.7 13.4 17.3
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
US
Pfizer Inc
NYSE:PFE
159.7B USD 2.6 20.9 7.9 10.6
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.3 7.6 8.9
US
Bristol-Myers Squibb Co
NYSE:BMY
124.3B USD 2.6 17.6 7.4 9.1
FR
Sanofi SA
PAR:SAN
100.1B EUR 2.1 12.8 10.7 10.7
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
SIX:LLY
Average P/E: 21.5
43.7
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.4
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30.6
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
CH
Novartis AG
SIX:NOVN
21.7
14%
1.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.9
22%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
17.6
16%
1.1
FR
Sanofi SA
PAR:SAN
12.8
16%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
SIX:LLY
Average EV/EBITDA: 46
29.5
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.9
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.4
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.9
-9%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-10%
N/A
FR
Sanofi SA
PAR:SAN
10.7
19%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
SIX:LLY
Average EV/EBIT: 99.7
31.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
13
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23.8
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2.1
CH
Novartis AG
SIX:NOVN
17.3
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
-4%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.5
US
Bristol-Myers Squibb Co
NYSE:BMY
9.1
-7%
N/A
FR
Sanofi SA
PAR:SAN
10.7
12%
0.9
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett